The data presented in this article are related to the research article entitled "Patients aged 90 years or older with atrial fibrillation treated with oral anticoagulants: A multicentre observational study" [1] . This article unveils original data of a cohort of 546 patients aged 90 years or older with non-valvular atrial fibrillation treated with oral anticoagulants. Here, we describe the time course of ischemic stroke and systemic embolism and of major bleeding according to the presence of outcome predictors and report the causes of permanent discontinuation and of death. Furthermore, we report data on the incidence of ischemic stroke and systemic embolism, of major bleeding, of permanent discontinuation and of all-cause death comparing i) oral anticoagulant naïve users vs. long-term oral anticoagulant users, ii) patients on anticoagulant therapy for less than 2 years (new users) vs. patients on anticoagulant therapy for more than 2 years. The material of this data article provides a better understanding on the use of oral anticoagulants in this fragile population and facilitates further critical analysis. Moreover, it aims at highlighting the importance of increasing knowledge in patients aged 90 years or older. These DOI of original article: https://doi
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Data
The dataset of this article comprises five data files that were generated from further analysis of 546 patients aged 90 years or older with atrial fibrillation treated with oral anticoagulants. Fig. 1 shows the selection of the population with the number of patients divided according to type [direct oral anticoagulants (DOAC) or vitamin-K antagonist (VKA)] and duration (already on anticoagulant or naïve) of oral anticoagulation. The time course of ischaemic stroke/TIA and systemic embolism (panel A) and for major bleeding (panel B) according to the presence of outcome predictors are given in Fig. 2 . Main causes of permanent discontinuation in the overall population and according to the type of anticoagulation received are shown in Table 1 . The same table reports the percentages of patients that discontinued anticoagulants or died and the annual incidence rates of discontinuation and death. Data on hazard ratios and subdistribution hazard ratios of main predictors for permanent discontinuation are reported in Fig. 3 . Table 2 shows data on comparisons of sub-group of patients, specifically i) oral anticoagulant naïve users vs. long-term oral anticoagulant users and ii) patients on anticoagulant therapy for less than 2 years (new users) vs. patients on anticoagulant therapy for more than 2 years. Here, we report data in the overall population and according to treatment group. [1] .
Value of the data
The data presented in this article provide original information and increase knowledge on the use of oral anticoagulants in patients aged 90 years or older with atrial fibrillation. The data can be used by clinicians and researchers to generate hypothesis for further studies and as reference. These data could support the decision making process on the use of oral anticoagulation in patients aged 90 years or older. 
Experimental design, materials and methods
Data on DOAC patients were derived from a multicentre prospective Italian registry of atrial fibrillation patients [2] while data on VKA patients were retrospectively derived from the database of the Anticoagulation Clinic of Perugia. For both group, data were collected since time of anticoagulation prescription or since the patient became 90 years old. Follow-up was performed every 6 months by visits or telephone contacts in the DOAC group while follow-up was retrospectively retrieved in the VKA group. Due to the expected high mortality of study patients, we performed a time-to-event analyses taking death as competing risk. We calculated the cumulative incidences and the risks of a) ischemic stroke/ TIA and systemic embolism; b) major bleeding; c) permanent discontinuation. Data were reported as sub-distribution hazard ratios (SHR) and 95% confidence interval. Statistical analysis was performed using R 3.5.0.
